ClinicalTrials.gg
CompletedNCT07504705Updated Nov 3, 2026

Comparison of Intertransverse Process and Erector Spinae Plane Blocks in Acute Postoperative Analgesia Management for Laparoscopic Cholecystectomy Patients

An interventional study of Intertransverse Process Block and Erector Spinae Plane Block in Acut Postoperative Pain, Erector Spinae Plane Block and Intertransverse Process Block, sponsored by Konya City Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Konya City Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 3, 2026Now CompletedNow Active, not recruiting+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Pain, Postoperative by Konya City Hospital — 11 open to participants now, 11 under way, none of them phase 3. Pain, Postoperative · Konya City Hospital.

Enrollment
3rd of 18
110 · median 73
Started
2026
with 7 others
No phase
17 of 22
9 open now
Registered
16th of 22
by date

Among the 22 studies in Pain, Postoperative by Konya City Hospital, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is one of 8 that started in 2026, is one of 17 with no phase, and was the 16th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

11 of the 22 studies in Pain, Postoperative by Konya City Hospital are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Pain, Postoperative by Konya City Hospital, or all of them as a file.
02

Study summary

Laparoscopic cholecystectomy is considered the gold standard for the surgical treatment of benign gallbladder diseases; however, despite its minimally invasive nature, a significant proportion of patients experience substantial early postoperative pain, which impacts patient comfort and the duration of hospital stay. The current PROSPECT review and previous studies emphasize that this pain is multifactorial-comprising somatic, visceral, and phrenic nerve-mediated shoulder-tip components-and therefore advocate for an opioid-sparing multimodal analgesic approach. Within this framework, first-line recommendations include paracetamol, NSAIDs/COX-2 inhibitors, dexamethasone, and local anesthetic infiltration of the surgical site and/or intraperitoneal cavity, alongside appropriate regional blocks; opioids should be reserved solely for rescue analgesia.

Ultrasound-guided regional anesthesia blocks are increasingly utilized for acute visceral pain conditions, such as renal colic. The Erector Spinae Plane Block (ESPB) is an interfacial block performed in the thoracic paraspinal region, and it is hypothesized that its extensive spread may influence somatic and, to some extent, visceral pain pathways. Nevertheless, anatomical and clinical studies report inconsistent effects of ESPB on visceral pain, noting that local anesthetics may not consistently reach the paravertebral space, thereby leading to variable block efficacy.

Consequently, the Intertransverse Process Block (ITPB), which targets a plane anatomically closer to the paravertebral space, has been described in recent years as an alternative technique. ITPB is performed by injecting local anesthetic into the interfacial space adjacent to the retro-superior costotransverse ligament; it is reported to carry a low risk of complications as it does not require direct orientation toward the pleura or neuraxial structures. Clinical trials indicate that ITPB provides analgesic efficacy comparable to paravertebral blocks in both thoracic and abdominal surgeries and reduces opioid consumption. Furthermore, anatomical studies suggest that the probability of local anesthetic spread into the paravertebral space is higher with ITPB than with ESPB.

However, a randomized controlled trial comparing ESPB and ITPB in patients undergoing laparoscopic cholecystectomy is currently lacking in the literature. Therefore, the present study was designed to address this gap.

03

Conditions studied

  • Acut Postoperative Pain
  • Erector Spinae Plane Block
  • Intertransverse Process Block

Browse trials for

Keywords

  • Laparoscopic Cholecystectomy
  • Erector Spinae Plane Block
  • Intertransverse Process Block
  • Postoperative Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing elective laparoscopic cholecystectomy
  • (BMI) between 18 and 35 kg/m²
  • (ASA) physical status score of I-III
  • Ability to provide written and verbal

Exclusion criteria

Exclusion Criteria:

  • Coagulopathy or use of anticoagulant medications
  • Infection at the injection site
  • Allergy to local anesthetics
  • Pregnancy or breastfeeding
  • Chronic opioid use or analgesic dependence
  • Severe cardiopulmonary disease or psychiatric disorders
  • Previous regional block performed within the last 24 hours
  • Patients requiring emergency surgery
  • Cases converted from laparoscopic surgery to open surgery
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Active comparator
    Erector Spinae Plane Block

    Procedure: Erector Spinae Plane Block

  • Active comparator
    Intertransverse Process Block

    Procedure: Intertransverse Process Block

Interventions

  • ProcedureIntertransverse Process Block

    The ITPB will be performed using the same ultrasound (US) device. Initially, the spinous process of the T8 vertebra will be visualized in the horizontal plane at the midline using a linear probe. The probe will then be shifted approximately 2 cm laterally to the right and left of the midline in the longitudinal plane to visualize the superior costotransverse ligament (SCTL) spanning between the transverse processes and the pleura. The block needle will be advanced in-plane in a caudal-to-cranial direction, parallel to the SCTL, and stopped just before reaching the cranial aspect of the eighth rib. After the space is confirmed via hydrodissection, 20 mL of 0.5% bupivacaine (not exceeding a maximum dose of 2.5 mg/kg) will be injected without penetrating the SCTL, while simultaneously monitoring the volume spread via US. The block will be performed unilaterally at the level of the right hemithorax.

  • ProcedureErector Spinae Plane Block

    The ESPB will be performed in the sitting position under ultrasound (US) guidance using a 6-10 MHz linear ultrasound probe (Mindray DC-60 Exp; Mindray Bio-Medical Electronics, Shenzhen, China). The transverse process and erector spinae muscles at the T8 level will be visualized in a longitudinal parasagittal plane. An echogenic 22 G, 80 mm needle (Stimuplex A, B. Braun, Melsungen, Germany) will be advanced in-plane in a caudal-to-cranial direction until contact is made with the transverse process beneath the erector spinae muscle. Following negative aspiration, 20 mL of 0.5% bupivacaine will be injected, ensuring visualization of the spread within the fascial plane. The block will be performed unilaterally on the right hemithorax.

06

What researchers measure

Primary outcomes

  1. NRS Score

    The primary objective of this study is to compare the effects of ESPB and ITPB techniques on Numeric Rating Scale (NRS) pain scores in patients undergoing laparoscopic cholecystectomy. You hypothesis is that NRS scores will be lower in patients receiving ITPB compared to the ESPB group, as the ITPB is expected to provide more extensive visceral analgesia. Pain Assessment: Numeric Rating Scale (NRS) Pain intensity will be reported using the Numeric Rating Scale (NRS): Scale Range: Scores range from a minimum of 0 to a maximum of 10. Interpretation: A score of 0 represents "no pain," while a score of 10 represents the "worst possible pain." Consequently, higher scores indicate a worse outcome (increased pain severity), while lower scores indicate superior analgesic efficacy.

    Time frame: 0 to 24 hours postoperatively

Secondary outcomes

  1. Opioid consumption

    The secondary objective of the study is to evaluate the effects of ESPB and ITPB on opioid consumption. The amounts of rescue analgesic (tramadol) administered in the post-block period will be recorded. You hypothesis is that opioid requirements will be lower in patients receiving ITPB compared to the ESPB group, due to the provision of more effective analgesia.

    Time frame: 0 to 24 hours postoperatively

07

Study locations

1 site
  • Konya City Hospital
    Konya, Konya 42290, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2026 to primary completion in Oct 2026, 5 months.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 5 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

Primary completion moved once since we started tracking on Sep 25, 2026: May 2027 → Oct 2026, on Oct 20, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: May 2027 → Nov 2026, last on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Apr 1, 2026
StartActual
May 7, 2026
Primary completionActual
Oct 17, 2026was May 2027
CompletionActual
Nov 2, 2026was May 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting→Completed
changed Oct 20, 2026 · changed Nov 3, 2026
Primary completion
May 1, 2027→Oct 17, 2026 (actual)
Oct 20, 2026
Study completion
May 25, 2027→Nov 2, 2026 (actual)
moved 2 times, Oct 20, 2026 – Nov 3, 2026
Show all 3 updates
  1. Nov 3, 2026
    Active, not recruiting→Completed
    Study completion Nov 1, 2026→Nov 2, 2026 (now actual)
  2. Oct 23, 2026
    Minor edits only
    + 1 other change: arm descriptions
  3. Oct 20, 2026
    Recruiting→Active, not recruiting
    Primary completion May 1, 2027→Oct 17, 2026 (now actual)
    Study completion May 25, 2027→Nov 1, 2026
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07504705
Lead sponsor
Konya City Hospital
Responsible party
Ömer Keklicek (principal investigator, Konya City Hospital) — Principal investigator
First posted
Apr 1, 2026
Start date
May 7, 2026
Primary completion
Oct 17, 2026
Completion
Nov 2, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion